Leading Biotechnology Company Enhances AWS Environment Security and Risk Control
Published on June 16, 2023
A leading biotechnology company that develops life-transforming medicines has worked for decades to improve the lives of those who rely on their work. But recently, they found themselves in need of assistance to enhance the security of their AWS environment.
The company had an insufficient understanding of their current security posture and needed additional assistance with risk control and reporting within AWS. The company also lacked a provisioned tenant that can perform a technical scan of their AWS environment and provide benchmarks against the CIS AWS v1.4 benchmark.
This client is a leading biotechnology and pharmaceutical/life sciences company that develops life-transforming medicines.
The client needed to enhance both the current security and understanding of its AWS environment, and the risk control and reporting within that environment. It also lacked a provisioned tenant that could perform a technical scan of its AWS environment and provide benchmarks against the CIS AWS v1.4 benchmark.
Protiviti interviewed the client’s cloud and information security teams, reviewed 30 AWS infrastructure documents, provided findings on the state of the client’s security structure and benchmarked all findings against the CIS AWS v1.4 framework.
Identified 2.5 million vulnerabilities and 10,500 issues. 35 infrastructure gaps were identified and mapped to 16 remediation plans. Compiled all findings, recommendations, benchmarks and roadmaps into a 100+ page report for the client.
Security scans revealed 2.5 million vulnerabilities and 10,500 issues, detailed in comprehensive reports and roadmaps for immediate remediation.